HK1243416A1 - 1-((2r,4r)-2-(1h-苯并[d]咪唑-2-基)-1-甲基呱啶-4-基)-3-(4-氰基苯基)脲马来酸盐的晶形 - Google Patents

1-((2r,4r)-2-(1h-苯并[d]咪唑-2-基)-1-甲基呱啶-4-基)-3-(4-氰基苯基)脲马来酸盐的晶形 Download PDF

Info

Publication number
HK1243416A1
HK1243416A1 HK18103046.8A HK18103046A HK1243416A1 HK 1243416 A1 HK1243416 A1 HK 1243416A1 HK 18103046 A HK18103046 A HK 18103046A HK 1243416 A1 HK1243416 A1 HK 1243416A1
Authority
HK
Hong Kong
Prior art keywords
ppm
values
crystalline form
maleate
peaks
Prior art date
Application number
HK18103046.8A
Other languages
English (en)
Chinese (zh)
Inventor
E.C.汉森
E.C.漢森
C.S.西德克
Original Assignee
辉瑞公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1243416(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 辉瑞公司 filed Critical 辉瑞公司
Publication of HK1243416A1 publication Critical patent/HK1243416A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18103046.8A 2015-04-24 2016-04-13 1-((2r,4r)-2-(1h-苯并[d]咪唑-2-基)-1-甲基呱啶-4-基)-3-(4-氰基苯基)脲马来酸盐的晶形 HK1243416A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562152108P 2015-04-24 2015-04-24
US62/152,108 2015-04-24
PCT/IB2016/052107 WO2016170451A1 (en) 2015-04-24 2016-04-13 Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate

Publications (1)

Publication Number Publication Date
HK1243416A1 true HK1243416A1 (zh) 2018-07-13

Family

ID=55806563

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103046.8A HK1243416A1 (zh) 2015-04-24 2016-04-13 1-((2r,4r)-2-(1h-苯并[d]咪唑-2-基)-1-甲基呱啶-4-基)-3-(4-氰基苯基)脲马来酸盐的晶形

Country Status (24)

Country Link
US (4) US10414748B2 (enExample)
EP (2) EP3286176B1 (enExample)
JP (1) JP6345728B2 (enExample)
KR (2) KR20190038677A (enExample)
CN (1) CN107531667A (enExample)
AR (1) AR104391A1 (enExample)
AU (1) AU2016251940C1 (enExample)
BR (1) BR112017021075B1 (enExample)
CA (2) CA2983387C (enExample)
CY (2) CY1124056T1 (enExample)
DK (2) DK3286176T3 (enExample)
ES (2) ES2774053T3 (enExample)
HK (1) HK1243416A1 (enExample)
HU (2) HUE059506T2 (enExample)
IL (1) IL255224B (enExample)
MX (1) MX375384B (enExample)
PL (2) PL3286176T3 (enExample)
PT (2) PT3286176T (enExample)
RU (1) RU2717564C2 (enExample)
SG (1) SG11201707863QA (enExample)
SI (2) SI3666768T1 (enExample)
TW (1) TWI646093B (enExample)
WO (1) WO2016170451A1 (enExample)
ZA (1) ZA201706391B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3286176B1 (en) 2015-04-24 2020-01-15 Pfizer Inc Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
US12668581B2 (en) * 2020-01-28 2026-06-30 Assia Chemical Industries Ltd. Processes for the preparation of Glasdegib and salt thereof and solid state forms of Glasdegib maleate and process for preparation thereof
WO2021191278A1 (en) 2020-03-26 2021-09-30 Lek Pharmaceuticals D.D. Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy
WO2023017541A1 (en) * 2021-08-12 2023-02-16 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methyl piperidin-4-yl)-3-(4-cyanophenyl)urea maleate
CN114668849B (zh) * 2021-12-31 2024-01-23 中国人民解放军军事科学院军事医学研究院 Shh通路调控生物节律及其相关应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US8253800B2 (en) 2006-06-28 2012-08-28 Nikon Corporation Tracking device, automatic focusing device, and camera
CA2690953C (en) * 2007-06-29 2012-10-02 Pfizer Inc. Benzimidazole derivatives
EP3286176B1 (en) 2015-04-24 2020-01-15 Pfizer Inc Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate

Also Published As

Publication number Publication date
CA2983387C (en) 2022-08-16
CY1124056T1 (el) 2022-03-24
DK3666768T3 (da) 2022-06-27
AR104391A1 (es) 2017-07-19
US20220024894A1 (en) 2022-01-27
BR112017021075A2 (pt) 2018-07-03
RU2017137269A3 (enExample) 2019-09-13
US11891373B2 (en) 2024-02-06
AU2016251940A1 (en) 2017-10-12
CA2983387A1 (en) 2016-10-27
ZA201706391B (en) 2020-12-23
JP2016204373A (ja) 2016-12-08
KR102078444B1 (ko) 2020-02-17
SI3666768T1 (sl) 2022-09-30
PT3286176T (pt) 2020-02-24
HUE059506T2 (hu) 2022-11-28
SG11201707863QA (en) 2017-11-29
AU2016251940B2 (en) 2018-08-30
MX375384B (es) 2025-03-06
ES2923593T3 (es) 2022-09-28
EP3666768B1 (en) 2022-06-15
US20190382368A1 (en) 2019-12-19
US10414748B2 (en) 2019-09-17
IL255224B (en) 2021-01-31
IL255224A0 (en) 2017-12-31
HUE048664T2 (hu) 2020-07-28
SI3286176T1 (sl) 2020-04-30
KR20170129245A (ko) 2017-11-24
DK3286176T3 (da) 2020-03-02
US20180086731A1 (en) 2018-03-29
CA2927736A1 (en) 2016-10-24
JP6345728B2 (ja) 2018-06-20
TWI646093B (zh) 2019-01-01
RU2717564C2 (ru) 2020-03-24
CN107531667A (zh) 2018-01-02
US11168066B2 (en) 2021-11-09
EP3286176B1 (en) 2020-01-15
MX2017013645A (es) 2018-03-08
RU2017137269A (ru) 2019-05-24
ES2774053T3 (es) 2020-07-16
PL3666768T3 (pl) 2022-09-19
AU2016251940C1 (en) 2019-04-11
PL3286176T3 (pl) 2020-11-30
US11891372B2 (en) 2024-02-06
KR20190038677A (ko) 2019-04-08
BR112017021075B1 (pt) 2021-08-03
NZ735719A (en) 2020-11-27
WO2016170451A1 (en) 2016-10-27
US20220024893A1 (en) 2022-01-27
TW201702238A (zh) 2017-01-16
CY1125333T1 (el) 2025-03-28
PT3666768T (pt) 2022-07-22
EP3666768A1 (en) 2020-06-17
EP3286176A1 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
US11891372B2 (en) Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
CN113260617A (zh) Cdk抑制剂的结晶形式
US10689380B1 (en) Crystalline forms of valbenazine ditosylate
JP2018502140A (ja) ベンズイミダゾール誘導体の新規結晶形及びその製造方法
EA029995B1 (ru) Новая кристаллическая форма соли 1-(5-(2,4-дифторфенил)-1-((3-фторфенил)сульфонил)-4-метокси-1h-пиррол-3-ил)-n-метилметанамина
CN111094241B (zh) 一种氧代吡啶酰胺类衍生物的晶型及其制备方法
WO2016172333A1 (en) A solid state form of perampanel
CN114853762B (zh) 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
KR102858471B1 (ko) Lta4h 저해제의 결정질 형태
NZ735719B2 (en) Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
UA114041C2 (xx) Сіль 3-$(3-{$4-(4-морфолінілметил)-1н-пірол-2-іл]метилен}-2-оксо-2,3-дигідро-1н-індол-5-іл)метил]-1,3-тіазолідин-2,4-діону, її отримання і композиції, що її містять
TW202527943A (zh) 2-(4-(2-(7,8-二甲基-[1,2,4]三唑[1,5-a]吡啶-6-基)-3-異丙基-1h-吲哚-5-基)哌啶-1-基)乙醯胺鹽及其結晶形式
KR20240149820A (ko) 오토탁신 억제제 화합물의 신규한 결정형
WO2023194547A1 (en) Birinapant polymorph h
HK40058992A (en) Crystalline form of a cdk inhibitor
HK40025351A (en) Crystal form of oxopicolinamide derivative and preparation method therefor
EA029298B1 (ru) Полиморфные формы n-карбамоилметил-4(r)-фенил-2-пирролидона